The goal of this study was to evaluate the effect of TLR4 antagonism on neuroinflammation and other markers of AD-relevant pathology in mice that express human APOE. To address this goal, we treated EFAD mice from 4 to 6 months of age (Prevention paradigm; PVT) or from 6 to 7 months of age (reversal paradigm; RVS) with either vehicle or IAXO-101 (10 mg/kg ~ 0.3 mg/mouse, 3 subcutaneous injections/week). This evidence concerns the gene TLR4 and Alzheimer disease.